A. Liapikou (Athens, Greece), R. Cosentini (Milan, Italy)
Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
G. Walters, H. S. Liu, M. Gemza, F. Rauf (Worcester, United Kingdom)
|   |
Biomarkers as complication predictors in community-acquired pneumonia
S. Fandos, E. Mincholé, A. Lasierra, A. L. Simon, E. Vera, M. A. Ruiz, S. Bello (Zaragoza, Spain)
| |
Community acquired pneumonia (CAP) mortality and biomarkers
A. B. Lasierra, S. Fandos, A. L. Simón, E. Mincholé, S. García, M. A. Ruiz, F. De Pablo, S. Bello (Zaragoza, Spain)
| |
Usefullness of CPR and PCT in the etiological diagnosis of community-acquired pneumonia
R. Moreno, B. Montull, E. Polverino, S. Reyes, J. M. Sahuquillo, J. G. Córdoba, R. Martinez, C. Cilloniz, A. Gimeno, J. Sellarés, M. A. Marcos, R. Menéndez, A. Torres (Valencia, Barcelona, Spain)
| |
Lactate is an independent marker of severity in hospitalised patients with community-acquired pneumonia
J. D. Chalmers, A. Singanayagam, A. Akram, P. Mandal, G. Choudhury, M. Smith, A. T. Hill (Edinburgh, United Kingdom)
| |
An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
S. Aliberti, L. C. Morlacchi, A. Gramegna, B. Dallari, S. Galbiati, R. Cosentini, A. M. Brambilla, F. Giuliani, A. Pesci, J. Bordon, F. Blasi (Monza, Milano, Italy; Washington, United States Of America)
| |
Biomarkers and community acquired pneumonia (CAP) severity
A. Lasierra, S. Fandos, E. Minchole, A. L. Simon, M. A. Ruiz, D. Nieto, E. Forcén, S. Bello (Zaragoza, Spain)
| |
Biomarkers to discriminate bacterial, viral and mixed community acquired pneumonia (CAP)
E. Mincholé, A. Lasierra, A. L. Simón, S. Fandos, M. A. Ruiz, V. Moya, F. De Pablo, S. Bello (Zaragoza, Spain)
| |
The ability of pro adrenomedullin to predict severe sepsis in patients with comunity-acquired pneumonia
A. Uranga, P. P. España, A. Capelastegui, I. Gorordo, R. Diez, A. Bilbao, C. Mar, E. Bereciartua, E. Bereciartua (Galdakao, Sondika, Spain)
| |
Pro-adrenomedullin, pro-atrial natriuretic peptide and procalcitonin levels at admission in patients with community-acquired pneumonia and its correlation with risk scores
A. Lacoma, A. Bas, P. Tudela, J. Dominguez, J. M. Mòdol, V. Ausina, C. Prat (Badalona, Spain)
| |
Inflammatory pattern in bacteriemic community-acquired pneumonia
B. Montull, R. Menéndez, E. Polverino, S. Reyes, J. M. Sahuquillo, J. G. Córdoba, C. Cilloniz, R. Martínez, R. Moreno, A. Torres, J. Sellares, M. A. Marcos (Valencia, Barcelona, Spain)
| |
C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis
A. Makarevich, O. Omelyanenko, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes
O. Omelyanenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia
A. Uranga, P. P. España, A. Capelastegui, I. Gorordo, R. Diez, A. Bilbao, C. Mar, E. Bereciartua (Galdakao, Sondika, Spain)
| |
Prognostic value of cortisol and adrenocorticotropic hormone (ACTH) in severe community-acquired pneumonia (SCAP) patients
O. Omelyanenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Interleukin-2 (IL-2) and interferon-γ(IF-γ) in idenitying severe community-acquired pneumonia (SCAP) clinical outcomes and complications
A. Makarevich, O. Omelyanenko, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Thyroid hormones implication in severe community-acquired pneumonia (SCAP): Relationship with survival, outcomes and clinical complications
O. Omelyanenko, A. Makarevich, E. Amelchenko, T. Rybina (Minsk, Belarus)
| |
Pro-adrenomedullin, procalcitonin and CRP levels to predict bacterial pneumonia in patients admitted to emergency room
A. Lacoma, C. Prat, P. Tudela, M. Giménez, A. Ramirez, J. M. Mòdol, J. Dominguez, V. Ausina (Badalona, Spain)
| |